CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Market Cap $798.1M Add to my watchlist

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

CUV	Initial Director's Interest Notice		26/11/19	155.49KB	Share
CUV	CLINUVEL appoints new Non-Executive Director		26/11/19	145.97KB	Share
CUV	Results of Meeting		20/11/19	128.21KB	Share
CUV	Managing Directors AGM Presentation		20/11/19	1.38MB	Share
CUV	Chair Address		20/11/19	141.39KB	Share
CUV	Change of Director's Interest Notice		06/11/19	211.1KB	Share
CUV	Appendix 3B		06/11/19	284.99KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/19	229.02KB	Share
CUV	TGA Priority Registration Pathway for SCENESSE	PRICE SENSITIVE	30/10/19	168.81KB	Share
CUV	Letter from the Remuneration Committee Chair		30/10/19	108.83KB	Share
CUV	CLINUVEL Chair to Retire Following FDA Approval		18/10/19	140.89KB	Share
CUV	Appendix 4G and Corporate Governance Statement		18/10/19	514.56KB	Share
CUV	Annual Report to shareholders		18/10/19	6.41MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		18/10/19	393.39KB	Share
CUV	CLINUVEL Newsletter		17/10/19	237.01KB	Share
CUV	Chair Letter to Shareholders		15/10/19	151.73KB	Share
CUV	Audio Transcript Investor Teleconference		10/10/19	123.83KB	Share
CUV	Media Release - FDA Approves SCENESSE for Genetic Disorder		09/10/19	155.66KB	Share
CUV	FDA Grants Marketing Approval for SCENESSE	PRICE SENSITIVE	09/10/19	151.07KB	Share
CUV	Trading Halt	PRICE SENSITIVE	08/10/19	322.51KB	Share
CUV	CLINUVEL renews CEO Employment Agreement	PRICE SENSITIVE	07/10/19	166.92KB	Share
CUV	FDA Clarifies SCENESSE PDUFA Date	PRICE SENSITIVE	02/10/19	131.25KB	Share
CUV	CLINUVEL Announces AGM Date		30/09/19	109.71KB	Share
CUV	Initial Director's Interest Notice		25/09/19	132.04KB	Share
CUV	CLINUVEL Appoints New Director		23/09/19	119.08KB	Share
CUV	SCENESSE presented at ICPP in Milan		10/09/19	153.09KB	Share
CUV	Change of Director's Interest Notice		03/09/19	192.43KB	Share
CUV	Dividend/Distribution - CUV	PRICE SENSITIVE	28/08/19	23.84KB	Share
CUV	CLINUVEL Clarifies ex-Dividend Date		28/08/19	135.54KB	Share
CUV	Appendix 4E and Preliminary Financial Report Reissued	PRICE SENSITIVE	28/08/19	1.94MB	Share
CUV	CLINUVEL declares Full Year Dividend	PRICE SENSITIVE	28/08/19	166.87KB	Share
CUV	Appendix 4E and Preliminary Financial Report	PRICE SENSITIVE	28/08/19	1.76MB	Share
CUV	CLINUVEL program discussed at Light and Life 2019 Conference		22/08/19	149.64KB	Share
CUV	CLINUVEL Newsletter		20/08/19	420.72KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/07/19	450.98KB	Share
CUV	Change in Composition to Audit and Risk Committee		25/07/19	125.24KB	Share
CUV	CLINUVEL Newsletter		11/07/19	424.01KB	Share
CUV	CLINUVEL Relocates Melbourne Office		21/06/19	109.27KB	Share
CUV	CLINUVEL included in S&P/ASX 200 Index		14/06/19	164.36KB	Share
CUV	S&P DJI Announces June 2019 Quarterly Rebalance	PRICE SENSITIVE	14/06/19	196.53KB	Share
CUV	Presentation Jefferies Healthcare Conference		07/06/19	1.08MB	Share
CUV	Lapse and forfeit of Unlisted Conditional Performance Rights		05/06/19	128.1KB	Share
CUV	Media Release-US FDA review for SCENESSE extended 3 months		03/06/19	115.77KB	Share
CUV	US FDA extends PDUFA date for SCENESSE	PRICE SENSITIVE	03/06/19	162.4KB	Share
CUV	Change of Director's Interest Notice		15/05/19	207.85KB	Share
CUV	Becoming a substantial holder		08/05/19	1.81MB	Share
CUV	CLINUVEL Newsletter		02/05/19	275.99KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/19	215.62KB	Share
CUV	Chair Letter to Shareholders		24/04/19	127.16KB	Share
CUV	Presentation Goldman Sachs Emerging Leaders Conference		04/04/19	1000.9KB	Share
CUV	CLINUVEL hosts European EPP Clinical Expert Meetings		29/03/19	133.56KB	Share
CUV	CLINUVEL Newsletter		20/03/19	266.73KB	Share
CUV	UK NICE Meeting Held		15/03/19	157.21KB	Share
CUV	Change in substantial holding		13/03/19	463.75KB	Share
CUV	Change in substantial holding		13/03/19	159.39KB	Share
CUV	Change of Director's Interest Notice x 3		13/03/19	269.38KB	Share
CUV	Appendix 3B		13/03/19	327.17KB	Share
CUV	Investor Briefing		04/03/19	1.21MB	Share
CUV	Appendix 4D Half Yearly Report	PRICE SENSITIVE	26/02/19	1.15MB	Share
CUV	CLINUVEL Vitiligo Communique II		12/02/19	495.12KB	Share
CUV	CLINUVEL Newsletter		07/02/19	272.31KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/19	212.51KB	Share
CUV	Change of Director's Interest Notice		29/01/19	244.01KB	Share
CUV	CLINUVEL Newsletter		15/01/19	356.98KB	Share
CUV	US FDA sets PDUFA date for SCENESSE	PRICE SENSITIVE	10/01/19	374.13KB	Share
CUV	CLINUVEL Vitiligo Communique		19/12/18	654.08KB	Share
CUV	CUV103 Singaporean Phase II vitiligo study results	PRICE SENSITIVE	19/12/18	506.48KB	Share
CUV	CLINUVEL Newsletter		12/12/18	448.41KB	Share
CUV	Results of Meeting		21/11/18	148.91KB	Share
CUV	Managing Director AGM Presentation		21/11/18	5.54MB	Share
CUV	Chairman's Address to Shareholders		21/11/18	146.76KB	Share
CUV	CLINUVEL Newsletter		05/11/18	339.55KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/18	445.37KB	Share
CUV	CLINUVEL expands Singapore laboratory facilities		29/10/18	369.58KB	Share
CUV	Appendix 4G and Corporate Governance Statement		19/10/18	961.94KB	Share
CUV	Annual Report to shareholders		19/10/18	2.37MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		19/10/18	497.23KB	Share
CUV	Appeal Upheld Against NICE Recommendation in England	PRICE SENSITIVE	10/10/18	359.12KB	Share
CUV	Investor Presentation Sachs 18th Biotech in Europe Forum		08/10/18	1.75MB	Share
CUV	Chair Letter to Shareholders		05/10/18	301.56KB	Share
CUV	Ceasing to be a substantial holder		04/10/18	132.9KB	Share
CUV	AGM Date		03/10/18	250.72KB	Share
CUV	CLINUVEL Initiate Variegate Porphyria Proof of Concept Study		01/10/18	476.32KB	Share
CUV	NASDAQ Int Des Virtual Investor Conference Presentation		20/09/18	1.73MB	Share
CUV	Ceasing to be a substantial holder		12/09/18	484.08KB	Share
CUV	Appendix 3B		11/09/18	551.41KB	Share
CUV	Investor Presentation NewsMakers Conference		10/09/18	1.08MB	Share
CUV	S&P DJI Announces September 2018 Quarterly Rebalance	PRICE SENSITIVE	07/09/18	141.53KB	Share
CUV	US FDA Update	PRICE SENSITIVE	05/09/18	465.98KB	Share
CUV	Change in substantial holding		04/09/18	307.95KB	Share
CUV	Dividend/Distribution - CUV		29/08/18	23.85KB	Share
CUV	CLINUVEL declares first dividend		29/08/18	370.4KB	Share
CUV	Appendix 4E and Preliminary Financial Report	PRICE SENSITIVE	29/08/18	1.11MB	Share
CUV	CLINUVEL Investor Summary		21/08/18	217.26KB	Share
CUV	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/18	444.44KB	Share
CUV	CLINUVEL Newsletter		27/07/18	450.93KB	Share
CUV	Change in substantial holding		17/07/18	356.04KB	Share
CUV	Change of Director's Interest Notice		06/07/18	579.76KB	Share
CUV	Change in substantial holding		04/07/18	755.13KB	Share
CUV	CLINUVEL completes SCENESSE FDA Filing	PRICE SENSITIVE	25/06/18	380.41KB	Share

CUV Initial Director's Interest Notice
26/11/19		155.49KB	Share
CUV CLINUVEL appoints new Non-Executive Director
26/11/19		145.97KB	Share
CUV Results of Meeting
20/11/19		128.21KB	Share
CUV Managing Directors AGM Presentation
20/11/19		1.38MB	Share
CUV Chair Address
20/11/19		141.39KB	Share
CUV Change of Director's Interest Notice
06/11/19		211.1KB	Share
CUV Appendix 3B
06/11/19		284.99KB	Share
CUV Appendix 4C - quarterly
31/10/19	PRICE SENSITIVE	229.02KB	Share
CUV TGA Priority Registration Pathway for SCENESSE
30/10/19	PRICE SENSITIVE	168.81KB	Share
CUV Letter from the Remuneration Committee Chair
30/10/19		108.83KB	Share
CUV CLINUVEL Chair to Retire Following FDA Approval
18/10/19		140.89KB	Share
CUV Appendix 4G and Corporate Governance Statement
18/10/19		514.56KB	Share
CUV Annual Report to shareholders
18/10/19		6.41MB	Share
CUV Notice of Annual General Meeting/Proxy Form
18/10/19		393.39KB	Share
CUV CLINUVEL Newsletter
17/10/19		237.01KB	Share
CUV Chair Letter to Shareholders
15/10/19		151.73KB	Share
CUV Audio Transcript Investor Teleconference
10/10/19		123.83KB	Share
CUV Media Release - FDA Approves SCENESSE for Genetic Disorder
09/10/19		155.66KB	Share
CUV FDA Grants Marketing Approval for SCENESSE
09/10/19	PRICE SENSITIVE	151.07KB	Share
CUV Trading Halt
08/10/19	PRICE SENSITIVE	322.51KB	Share
CUV CLINUVEL renews CEO Employment Agreement
07/10/19	PRICE SENSITIVE	166.92KB	Share
CUV FDA Clarifies SCENESSE PDUFA Date
02/10/19	PRICE SENSITIVE	131.25KB	Share
CUV CLINUVEL Announces AGM Date
30/09/19		109.71KB	Share
CUV Initial Director's Interest Notice
25/09/19		132.04KB	Share
CUV CLINUVEL Appoints New Director
23/09/19		119.08KB	Share
CUV SCENESSE presented at ICPP in Milan
10/09/19		153.09KB	Share
CUV Change of Director's Interest Notice
03/09/19		192.43KB	Share
CUV Dividend/Distribution - CUV
28/08/19	PRICE SENSITIVE	23.84KB	Share
CUV CLINUVEL Clarifies ex-Dividend Date
28/08/19		135.54KB	Share
CUV Appendix 4E and Preliminary Financial Report Reissued
28/08/19	PRICE SENSITIVE	1.94MB	Share
CUV CLINUVEL declares Full Year Dividend
28/08/19	PRICE SENSITIVE	166.87KB	Share
CUV Appendix 4E and Preliminary Financial Report
28/08/19	PRICE SENSITIVE	1.76MB	Share
CUV CLINUVEL program discussed at Light and Life 2019 Conference
22/08/19		149.64KB	Share
CUV CLINUVEL Newsletter
20/08/19		420.72KB	Share
CUV Appendix 4C - quarterly
31/07/19	PRICE SENSITIVE	450.98KB	Share
CUV Change in Composition to Audit and Risk Committee
25/07/19		125.24KB	Share
CUV CLINUVEL Newsletter
11/07/19		424.01KB	Share
CUV CLINUVEL Relocates Melbourne Office
21/06/19		109.27KB	Share
CUV CLINUVEL included in S&P/ASX 200 Index
14/06/19		164.36KB	Share
CUV S&P DJI Announces June 2019 Quarterly Rebalance
14/06/19	PRICE SENSITIVE	196.53KB	Share
CUV Presentation Jefferies Healthcare Conference
07/06/19		1.08MB	Share
CUV Lapse and forfeit of Unlisted Conditional Performance Rights
05/06/19		128.1KB	Share
CUV Media Release-US FDA review for SCENESSE extended 3 months
03/06/19		115.77KB	Share
CUV US FDA extends PDUFA date for SCENESSE
03/06/19	PRICE SENSITIVE	162.4KB	Share
CUV Change of Director's Interest Notice
15/05/19		207.85KB	Share
CUV Becoming a substantial holder
08/05/19		1.81MB	Share
CUV CLINUVEL Newsletter
02/05/19		275.99KB	Share
CUV Appendix 4C - quarterly
30/04/19	PRICE SENSITIVE	215.62KB	Share
CUV Chair Letter to Shareholders
24/04/19		127.16KB	Share
CUV Presentation Goldman Sachs Emerging Leaders Conference
04/04/19		1000.9KB	Share
CUV CLINUVEL hosts European EPP Clinical Expert Meetings
29/03/19		133.56KB	Share
CUV CLINUVEL Newsletter
20/03/19		266.73KB	Share
CUV UK NICE Meeting Held
15/03/19		157.21KB	Share
CUV Change in substantial holding
13/03/19		463.75KB	Share
CUV Change in substantial holding
13/03/19		159.39KB	Share
CUV Change of Director's Interest Notice x 3
13/03/19		269.38KB	Share
CUV Appendix 3B
13/03/19		327.17KB	Share
CUV Investor Briefing
04/03/19		1.21MB	Share
CUV Appendix 4D Half Yearly Report
26/02/19	PRICE SENSITIVE	1.15MB	Share
CUV CLINUVEL Vitiligo Communique II
12/02/19		495.12KB	Share
CUV CLINUVEL Newsletter
07/02/19		272.31KB	Share
CUV Appendix 4C - quarterly
31/01/19	PRICE SENSITIVE	212.51KB	Share
CUV Change of Director's Interest Notice
29/01/19		244.01KB	Share
CUV CLINUVEL Newsletter
15/01/19		356.98KB	Share
CUV US FDA sets PDUFA date for SCENESSE
10/01/19	PRICE SENSITIVE	374.13KB	Share
CUV CLINUVEL Vitiligo Communique
19/12/18		654.08KB	Share
CUV CUV103 Singaporean Phase II vitiligo study results
19/12/18	PRICE SENSITIVE	506.48KB	Share
CUV CLINUVEL Newsletter
12/12/18		448.41KB	Share
CUV Results of Meeting
21/11/18		148.91KB	Share
CUV Managing Director AGM Presentation
21/11/18		5.54MB	Share
CUV Chairman's Address to Shareholders
21/11/18		146.76KB	Share
CUV CLINUVEL Newsletter
05/11/18		339.55KB	Share
CUV Appendix 4C - quarterly
31/10/18	PRICE SENSITIVE	445.37KB	Share
CUV CLINUVEL expands Singapore laboratory facilities
29/10/18		369.58KB	Share
CUV Appendix 4G and Corporate Governance Statement
19/10/18		961.94KB	Share
CUV Annual Report to shareholders
19/10/18		2.37MB	Share
CUV Notice of Annual General Meeting/Proxy Form
19/10/18		497.23KB	Share
CUV Appeal Upheld Against NICE Recommendation in England
10/10/18	PRICE SENSITIVE	359.12KB	Share
CUV Investor Presentation Sachs 18th Biotech in Europe Forum
08/10/18		1.75MB	Share
CUV Chair Letter to Shareholders
05/10/18		301.56KB	Share
CUV Ceasing to be a substantial holder
04/10/18		132.9KB	Share
CUV AGM Date
03/10/18		250.72KB	Share
CUV CLINUVEL Initiate Variegate Porphyria Proof of Concept Study
01/10/18		476.32KB	Share
CUV NASDAQ Int Des Virtual Investor Conference Presentation
20/09/18		1.73MB	Share
CUV Ceasing to be a substantial holder
12/09/18		484.08KB	Share
CUV Appendix 3B
11/09/18		551.41KB	Share
CUV Investor Presentation NewsMakers Conference
10/09/18		1.08MB	Share
CUV S&P DJI Announces September 2018 Quarterly Rebalance
07/09/18	PRICE SENSITIVE	141.53KB	Share
CUV US FDA Update
05/09/18	PRICE SENSITIVE	465.98KB	Share
CUV Change in substantial holding
04/09/18		307.95KB	Share
CUV Dividend/Distribution - CUV
29/08/18		23.85KB	Share
CUV CLINUVEL declares first dividend
29/08/18		370.4KB	Share
CUV Appendix 4E and Preliminary Financial Report
29/08/18	PRICE SENSITIVE	1.11MB	Share
CUV CLINUVEL Investor Summary
21/08/18		217.26KB	Share
CUV Appendix 4C - quarterly
30/07/18	PRICE SENSITIVE	444.44KB	Share
CUV CLINUVEL Newsletter
27/07/18		450.93KB	Share
CUV Change in substantial holding
17/07/18		356.04KB	Share
CUV Change of Director's Interest Notice
06/07/18		579.76KB	Share
CUV Change in substantial holding
04/07/18		755.13KB	Share
CUV CLINUVEL completes SCENESSE FDA Filing
25/06/18	PRICE SENSITIVE	380.41KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $15.78		Change 0.160(1.02%)		Mkt cap ! $798.1M

Open	High	Low	Value	Volume
$15.68	$15.98	$15.61	$1.005M	63.76K

Buyers (Bids)

No.	Vol.	Price($)
4	134	$15.75

Sellers (Offers)

Price($)	Vol.	No.
$15.78	74	6

View Market Depth

No.	Vol.	Price($)
3	118	15.750
1	3	15.740
4	230	15.730
5	279	15.720
5	821	15.710

Price($)	Vol.	No.
15.770	91	11
15.780	41	2
15.790	201	3
15.800	213	4
15.810	103	2

Last trade - 13.29pm 28/05/2024 (20 minute delay)


Last $15.75		Change 0.160 ( 0.68 %)
Open	High	Low	Volume
$15.68	$15.97	$15.61	2853
Last updated 13.46pm 28/05/2024 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available